Home > Insider Trading > Filing (0001209191-23-013004)

Filing Details

Accession Number:: 0001209191-23-013004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-24 20:34:17
Reporting Period:: 2023-02-23

Accepted Time:: 2023-02-24 20:34:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1202102	A George Scangos	C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-02-23	12,631	$25.97	183,608	No	4	S	Direct
Common Stock	Disposition	2023-02-24	4,239	$22.74	179,369	No	4	S	Direct
Common Stock	Disposition	2023-02-24	10,880	$23.56	168,489	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,533,629	Indirect	See footnote
Common Stock	179,930	Indirect	See footnote
Common Stock	111,644	Indirect	See footnote
Common Stock	827,151	Indirect	See footnote
Common Stock	111,644	Indirect	See footnote
Common Stock	827,151	Indirect	See footnote

Footnotes

Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.195 to $23.160 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.215 to $24.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.